Samatatug Biosimilar – Anti-Tissue factor mAb – Research Grade from ProteoGenix; catalogue PX-TA2213; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Samatatug Biosimilar – Anti-Tissue factor mAb – Research Grade is a therapeutic antibody that has been developed to target and inhibit tissue factor, a protein involved in blood clotting. This biosimilar is a highly specific and potent medication that has potential applications in various therapeutic areas. In this article, we will explore the structure, activity, and potential applications of Samatatug Biosimilar.
Samatatug Biosimilar is a monoclonal antibody, meaning it is produced by a single clone of immune cells. It is a biosimilar of the anti-tissue factor monoclonal antibody, which means it is highly similar to the original therapeutic antibody in terms of structure, function, and efficacy. The antibody consists of two heavy chains and two light chains, connected by disulfide bonds. The heavy chains are responsible for binding to the target protein, while the light chains provide stability to the antibody.
The structure of Samatatug Biosimilar is designed to specifically bind to tissue factor, a protein found on the surface of cells involved in blood clotting. The antibody has a high affinity for tissue factor, meaning it binds to it with a strong and specific interaction. This allows for effective targeting and inhibition of tissue factor, leading to the desired therapeutic effects.
Samatatug Biosimilar exerts its activity by binding to tissue factor and preventing it from interacting with other proteins involved in the blood clotting process. This action results in the inhibition of blood clot formation, which can be beneficial in various therapeutic settings.
In addition to its anti-clotting activity, Samatatug Biosimilar has also been shown to have anti-inflammatory effects. It can block the production of inflammatory proteins and reduce inflammation in various disease states. This makes it a potential therapeutic option for conditions characterized by excessive inflammation, such as autoimmune diseases.
Samatatug Biosimilar has potential applications in various therapeutic areas, including cardiovascular diseases, cancer, and autoimmune disorders. In cardiovascular diseases, it can be used to prevent and treat blood clots, which can lead to heart attacks and strokes. In cancer, Samatatug Biosimilar can be used to inhibit tumor growth and metastasis by targeting the tissue factor expressed on cancer cells.
In autoimmune disorders, Samatatug Biosimilar can be used to suppress inflammation and alleviate symptoms. It has shown promising results in preclinical studies for conditions such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease.
Samatatug Biosimilar – Anti-Tissue factor mAb – Research Grade is a highly specific and potent therapeutic antibody designed to target and inhibit tissue factor. Its structure allows for strong and specific binding to the target protein, and its activity leads to anti-clotting and anti-inflammatory effects. With its potential applications in various therapeutic areas, Samatatug Biosimilar has the potential to improve patient outcomes and provide a valuable treatment option for many diseases.
Keywords: Samatatug Biosimilar, Anti-Tissue factor mAb, therapeutic antibody, therapeutic target, structure, activity, applications.
ProteoGenix catalogue number PX-TA2213. For research use only.
Target: Samatatug Biosimilar – Anti-Tissue factor mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >95% by SDS-PAGE; Buffer: 0.01M PBS, pH 7.4; Applications: ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Samatatug Biosimilar – Anti-Tissue factor mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
